Á¦10ȸ ¿µ³²´ëÇб³º´¿ø ½ÉÀå³»°ú ½ÉÆ÷Áö¾ö : 2024-02-03
±³À°ÀÏÀÚ : 2024-02-03
±³À°Àå¼Ò : ´ë±¸ ±×·£µå È£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ
±³À°ÁÖÁ¦ : Á¦10ȸ ¿µ³²´ëÇб³º´¿ø ½ÉÀå³»°ú ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ¿µ³²´ëÇб³º´¿ø
½ÃÇà±â°ü(ÁöºÎ/°ú) : ³»°ú
´ã´çÀÚ : ³²Á¾È£
¿¬¶ôó : 010-9064-5960
À̸ÞÀÏ : 16njh@naver.com
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 13:00~13:15 Lifetime management of patients with severe AS ±è¿õ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 13:15~13:30 Management strategies for heavily calcified coronary artery stenosis ¹ÚÁ¾ÀÏ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 13:30~13:50 Treatment strategies for coronary bifurcation lesions Á¤¼ºÀ±(¿ï»êµ¿°)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 13:50~14:00 Åä·Ð Á¶Çö¼ö(Æ÷Ç×¼¼¸í±âµ¶)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 14:00~14:15 How to set up TEER for MR in our echo lab È«±×·ç(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 14:15~14:30 Assessment of true severity of AS: Case-based learning ¼ÕÀå¿ø(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 14:30~14:50 Advances in assessment of secondary TR ³²Á¾È£(¿µ³²ÀÇ´ë)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 14:50~15:00 Åä·Ð ÀÌ¿øÀç(¿µ³²ÀÇ´ë)
ÈÞ½Ä 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 15:00~15:20 ÈÞ½Ä ( )
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 15:20~15:35 PACs: clinical implication, diagnosis, and treatment ¹Ú±Ôȯ(´ë±¸º¸ÈÆ)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 15:35~15:50 Indication for conduction system pacing Á¶¹Î¼ö(¼¿ï¾Æ»ê)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 15:50~16:10 Single shot technique for rhythm control of AF ±èÈ«ÁÖ(¿¬¼¼ÀÇ´ë)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 16:10~16:20 Åä·Ð ÀÌ»óÈñ(Æ÷Ç×¼¼¸í±âµ¶)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 16:20~16:35 Recent Update of New Drugs in HF: Vericiguat and Mavacamten °»ó¿í(´ë±¸º¸ÈÆ)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 16:35~16:50 What¡¯s new and what has changed in 2023 ESH HTN guideline? ÀÌÇö¿í(°è¸íÀÇ´ë)
±³À°½Ã°£ 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 16:50~17:10 Obesity in HF ÃÖ°¿î(¿µ³²ÀÇ´ë)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 17:10~17:20 Åä·Ð ¹èÁØÈ£(Æ÷Ç×¼¼¸í±âµ¶)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 17:20~17:35 Case-based discussion : coronary artery anomaly ±èÈÆÅÂ(Æ÷Ç×¼¼¸í±âµ¶)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 17:35~17:50 Case-based discussion : coronary artery intervention ±èº´ÁØ(â¿øÇѸ¶À½)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 17:50~18:10 Case-based discussion : peripheral artery intervention ¹Ú¼¼Çö(´ë±¸º¸ÈÆ)
Åä·Ð 02¿ù 03ÀÏ ´ë±¸±×·£µåÈ£ÅÚ 2Ãþ ´ÙÀ̳ʽºÆ¼ BȦ 18:10~18:20 Åä·Ð ¼ÕÀå¿ø(¿µ³²ÀÇ´ë)